10-Q: Shuttle Pharmaceuticals Reports Q1 2025 Results, Highlights $5 Million Equity Financing

Shuttle Pharmaceuticals Holdings, Inc. announces its financial results for the first quarter of 2025, showcasing a recent $5 million equity financing and ongoing clinical trial developments.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. reported its financial results for the three months ended March 31, 2025.
• The company incurred a net loss of approximately $3.0 million and had no revenues for the quarter.
• As of March 31, 2025, the company's working capital was approximately $3.2 million.
• In February 2025, the company entered into a revolving loan agreement for up to $2.0 million.
• In March 2025, the company completed an equity raise that provided $5.0 million in net cash proceeds.
• The company's existing cash resources, proceeds from the equity offering, and available financing are not expected to be sufficient to fund operations and clinical trials for the next twelve months.
• The company's ability to continue as a going concern is dependent on raising additional equity or debt financing.
• Research and development expenses increased to $1.6 million, primarily due to clinical trial initiation costs.
• General and administrative expenses increased to $0.6 million, driven by stock-based compensation and marketing expenses.
• Legal and professional expenses increased to $0.8 million, mainly due to corporate matters and accounting expenses.
• The company is working to regain compliance with Nasdaq listing requirements, including the minimum bid price and stockholders' equity requirements.
• The company commenced its Phase II clinical study in October 2024.
• The company appointed an Interim CEO during the quarter.
• The company is party to a sponsored research agreement with the University of California, San Francisco, committing $0.3 million for research on prostate cancer models.
• The company entered into a consulting agreement with IR Agency LLC for marketing and advertising services, paying $2.0 million on April 5, 2025.
• Through May 8, 2025, holders exercised prefunded warrants, resulting in the issuance of 4,426,000 shares of common stock.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company secured financing, it is still operating at a loss and faces challenges in maintaining Nasdaq compliance and funding future operations.

Positives

• The company successfully completed a $5.0 million equity financing in March 2025.
• The company secured a revolving loan agreement for up to $2.0 million.
• The company commenced its Phase II clinical study in October 2024.
• The company has $4.5 million in cash and cash equivalents as of March 31, 2025.
• The company is actively working to regain compliance with Nasdaq listing requirements.

Negatives

• The company reported a net loss of $3.0 million for the three months ended March 31, 2025.
• The company has no revenues for the three months ended March 31, 2025.
• The company's existing cash resources are not expected to be sufficient to fund operations and clinical trials for the next twelve months.
• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's disclosure controls and procedures were, and continue to be, ineffective as of March 31, 2025.
• The company identified material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may not be able to regain compliance with Nasdaq listing requirements, potentially leading to delisting.
• The company's clinical trials may not be successful.
• The company's products may not receive regulatory approval.
• The company's disclosure controls and procedures were, and continue to be, ineffective as of March 31, 2025.
• The company identified material weaknesses in its internal controls over financial reporting.

Future Outlook

The company's existing cash resources, proceeds from the equity offering, and available financing are not expected to be sufficient to fund operations and clinical trials for the next twelve months, and the company's ability to continue as a going concern is dependent on raising additional equity or debt financing.

Industry Context

The company operates in the competitive pharmaceutical industry, focusing on cancer therapies. The company's success depends on its ability to develop and commercialize unique drugs, obtain regulatory approvals, and secure additional funding.

Comparison to Industry Standards

• Given the early stage of Shuttle Pharmaceuticals and its focus on clinical trials, direct comparison to established pharmaceutical companies is challenging.
• Comparable companies in the biotechnology sector often have high R&D expenses and net losses during the development phase.
• The $5 million equity financing provides a runway for continued operations, but further capital raises may be necessary, which is common for companies in this sector.
• Companies like Celldex Therapeutics and Novocure, which are also focused on cancer therapies, serve as benchmarks for clinical development and regulatory pathways.

Management Changes

Related Party Transactions

• On October 14, 2024, as part of the senior convertible note offering described in Note 5, the Company entered into a loan with an officer of the Company in the amount of $ 250,000 (principal) with an interest rate of 14.5 % per annum due October 13, 2025 , and warrants to purchase 100,382 shares of common stock at an exercise price of $ 1.40 per share.
• On September 4, 2024, the Company issued a $ 250,000 promissory note (the Promissory Note) to an officer of the Company for $ 250,000 . The Promissory Note accrues interest at 12 % per annum and is repayable in 12 substantially equal installments over a period of one year.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential delisting from Nasdaq.
• Employees' job security is dependent on the company's ability to secure additional funding.
• Patients may benefit from the successful development and commercialization of the company's cancer therapies.
• Creditors face the risk of non-payment if the company is unable to raise additional capital.

Next Steps

• The company will continue to pursue clinical development of Ropidoxuridine.
• The company will seek to raise additional capital to fund operations and clinical trials.
• The company will work to regain compliance with Nasdaq listing requirements.
• The company will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional improvements as necessary.

Key Dates

Keywords

Shuttle Pharmaceuticals, financial results, equity financing, clinical trials, Ropidoxuridine, Nasdaq compliance, going concern, net loss, research and development, convertible notes, warrants